Laboratorios Farmaceuticos ROVI SA
MAD:ROVI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Laboratorios Farmaceuticos ROVI SA
Cash from Financing Activities
Laboratorios Farmaceuticos ROVI SA
Cash from Financing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Laboratorios Farmaceuticos ROVI SA
MAD:ROVI
|
Cash from Financing Activities
-€47.8m
|
CAGR 3-Years
32%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
N/A
|
|
|
Almirall SA
MAD:ALM
|
Cash from Financing Activities
-€87.1m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-2%
|
|
|
F
|
Faes Farma SA
MAD:FAE
|
Cash from Financing Activities
€273.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Laboratorio Reig Jofre SA
MAD:RJF
|
Cash from Financing Activities
€16.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
11%
|
CAGR 10-Years
7%
|
|
|
L
|
Labiana Health SA
MAD:LAB
|
Cash from Financing Activities
€571.7k
|
CAGR 3-Years
-68%
|
CAGR 5-Years
-50%
|
CAGR 10-Years
N/A
|
|
Laboratorios Farmaceuticos ROVI SA
Glance View
Laboratorios Farmacéuticos ROVI SA has carved a niche for itself in the pharmaceutical industry through its focus on researching, developing, manufacturing, and marketing a broad range of small molecule drugs and specialized products. Founded in Spain, ROVI has channeled its efforts towards creating innovative solutions in the healthcare sector, with heparin-based products emerging as a cornerstone of its portfolio. The company's operational model is built on vertical integration, allowing it to control the entire lifecycle of its offerings, from production to commercialization. This approach not only ensures quality and compliance with stringent regulatory standards but also enables ROVI to adapt nimbly to market demands and leverage its proprietary science to secure a competitive edge. The revenue streams of ROVI are diversified across its proprietary products, contract manufacturing services, and its portfolio of licensed products. A significant portion of revenue stems from its commitment to injectable drug products like Bemiparin, a low molecular weight heparin, which has found a foothold in various international markets. Moreover, ROVI capitalizes on partnerships and alliances with major pharmaceutical giants, augmenting its contract manufacturing capabilities and tapping into more extensive distribution networks. Not resting on its laurels, ROVI invests heavily in research and development to fortify its pipeline with innovative formulations, thus ensuring sustained growth and a resilient positioning in the global pharmaceutical landscape. This blend of strategic partnerships, internal innovation, and market-responsive production underscores ROVI's business model and revenue generation prowess.
See Also
What is Laboratorios Farmaceuticos ROVI SA's Cash from Financing Activities?
Cash from Financing Activities
-47.8m
EUR
Based on the financial report for Dec 31, 2025, Laboratorios Farmaceuticos ROVI SA's Cash from Financing Activities amounts to -47.8m EUR.
What is Laboratorios Farmaceuticos ROVI SA's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
-17%
Over the last year, the Cash from Financing Activities growth was 14%. The average annual Cash from Financing Activities growth rates for Laboratorios Farmaceuticos ROVI SA have been 32% over the past three years , -17% over the past five years .